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r p f  Benzene is an important commercial commodity and has become widespread in 
--- ' the environments of developed countries.
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In the United States, gasoline contains up to 2% benzene by volume; in other 
countries, the benzene concentration in gasoline may be as high as 5%.
Benzene in the workplace has been associated with aplastic anemia and leukemia 
---■ and may also cause nonhematologic cancers.
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Benzene toxicity
A 50-year-old diesel m echanic with recurring nosebleeds, fatigue, and weight loss
A so-year-old man is prompted to visit your office because of a nosebleed that has been recurring for 2 days. 
He says that th is is the th ird episode of nosebleeds in the last 6 months. He expresses concern that he 
becomes easily fatigued at work, and 2 months ago he began noticing bruises on his arms and legs, 
although he does not recall the causes. He has lost more than 12 pounds in the last 2 years, which he 
attributes to loss of appetite.
H istory of previous illness includes a fractured arm in childhood. He has had three bad colds in the past 
2 years that lasted for more than a week and included coughing and breathing difficulty. The patient 
occasionally drinks beer; he quit smoking cigarettes 4 years ago. He does not have allergies and is taking 
no m edications at th is time.
On exam ination, you find a m uscular man w ith somewhat pale and dry skin. Conjunctivae are pale. 
Numerous ecchymoses and petechiae are noted on arms and legs. Many seem to be old w ith incomplete 
healing. BP is 138/84; HR is 94. Temperature is normal. His throat is moderately inflamed, and prominent 
cervical nodes are palpable. Examination is otherwise w ithin normal lim its.
On further questioning, you learn that the patient is a diesel mechanic and has worked on trucks for the same 
em ployer fo r the previous 12 years. He and his w ife divorced 8 years ago; his w ife became nervous and 
w ithdrawn a fter two m iscarriages, which led to marital stress. He has lived in his home for the past 16 years. 
He has a daughter, age 16, who lives with his ex-wife.
Laboratory studies reveal the fo llow ing: glucose, BUN, and bilirubin w ithin normal lim its; Hgb 10.2 g/dL 
(normal 14.0-18.0); Hct 32.6% (44.8-52.0); RBC 3.32 m il/mm3 (4.3-6.0); MCV 98 fl (80-100); MCH 31 pg (26-31); 
MCHC 31% (31-36); WBC 1500 mm3 (5000-10,000); segs 60% (40-60); bands 1% (0-5); lymphs 31% (20-40); 
monos 8% (4-8); p latelets 50 ,000/m m 3 (150,000-400,ooo). A chest X ray is negative except fo r some 
suggestion of hyperlucency; ECG is normal.
(a) What is the prob lem  lis t fo r this patien t?  What is the d iffe rentia l d iagnosis?
(b) What additional testing would you recommend?
(c) What m easures would you take to manage the case and treat this patient?
Answers to the Pretest can be found in Challenge answers (3) through (7) on pages 17 and 18.
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Exposure Pathways
= ^ t s d r _____________________________________
□  Benzene Is commonly used 
as a solvent and as a raw 
material in chemical 
syntheses.
□  Benzene Is added to unleaded 
motor fuels for its antiknock 
characteristics.
□  Because benzene plays such 
a vital role in many industrial 
processes and is a component 
of gasoline, it is widespread 
in the environment.
Benzene (C6H6) is the first member of a series of aromatic 
hydrocarbons recovered from refinery streams during catalytic 
reformation and other petroleum processes. It is a clear, color­
less, highly flammable liquid at room temperature. Its vapor is 
heavier than air and can travel to a source of ignition and flash 
back. It has a pleasant odor detectable at concentrations greater 
than 4 parts per million (ppm). (The workplace permissible expo­
sure level [PEL] is 1 ppm). Common synonyms for benzene include 
benzol, cyclohexatriene, phenyl hydride, and coal tar naphtha.
Benzene is one of the world ’s major commodity chemicals. Its 
primary use (85% of production) is as an intermediate in the 
production of other chemicals, predominantly styrene (for styro­
foam and other plastics), cumene (for various resins), and cyclo- 
hexane (for nylon and other synthetic fibers). Benzene is an 
important raw material fo r the manufacture of synthetic rubbers, 
gums, lubricants, dyes, pharmaceuticals, and agricultural chemi­
cals.
Benzene is a natural component of crude and refined petroleum. 
The mandatory decrease of lead alkyls in gasoline has led to an 
increase in the aromatic hydrocarbon content of gasoline to 
maintain high octane levels and antiknock properties. In the 
United States, gasoline typically contains less than 2% benzene 
by volume, but in other countries the benzene concentration may 
be as high as 5%.
Because of its lipophilic nature, benzene is an excellent solvent. 
Its use in paints, thinners, inks, adhesives, and rubbers, however, 
is decreasing and now accounts fo r less than 2% of current 
benzene production. Benzene was also an important component 
of many industrial cleaning and degreasing formulations but now 
is replaced mostly by toluene, chlorinated solvents, or mineral 
spirits. Although benzene is no longer added in significant quan­
tities to most commercial products, traces of it may still be present 
as a contaminant.
Because of its many uses, benzene is widespread in the environ­
ment. It is a component of both indoor and outdoor air pollution. 
Benzene levels measured in ambient air have ranged from less 
than 0.001 ppm in pristine rural areas to more than 0.1 ppm in 
urban areas. Sources of benzene in air are usually associated 
with chemical manufacturing or gasoline, including gasoline bulk- 
loading and discharging facilities and combustion engines (such 
as in automobiles, lawn mowers, and snow blowers). In almost all 
cases, benzene levels inside residences oroffices are higherthan 
levels outside. Benzene levels are also usually higher in homes 
with attached garages and those occupied by smokers. In the fall
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and w inter when buildings are less-well ventilated, benzene 
levels are even higher. The Environmental Protection Agency 
(EPA) classifies benzene as a Group A* carcinogen and has 
estimated that a lifetime exposure to 0.004 ppm benzene in air w ill 
result in, at most, 1 additional case of leukemia in 10,000 people 
exposed. (EPA risk estimates assume there is no threshold for 
benzene's carcinogenic effects.)
Leakage from  underground storage tanks and seepage from 
landfills o r im proper disposal of hazardous wastes has resulted 
in benzene contam ination of groundwater used for drinking. 
Effluent from  industries is also a source of ground-water con­
tam ination. EPA’s Office of Drinking W ater has estimated that 
l i f e t i m e  e x p o s u r e  t o  a b e n z e n e  c o n c e n t r a t i o n  of  
68 parts per billion (ppb) in drinking water would correspond to, at 
most, 1 additional cancer case in 10,000 people exposed. (The 
current EPA maximum contam inant level [MCL] for benzene in 
drinking w ater is 5 ppb.) In addition to being ingested, benzene in 
water can also be absorbed through wet skin and inhaled as it 
volatilizes during showering or laundering.
Persons who smoke one pack of cigarettes a day inhale a daily 
dose of approxim ately 1 m illigram  of benzene, which is about 
one-th irtie th  of the daily amount inhaled by a worker exposed at 
the currently perm issible workplace level.
* Group A consists of agents for which sufficient evidence supports a causal 
association between exposure and cancer in humans and in experimental 
animals.
(1) Later, the pa tien t in the case study tells you that his well water has always tasted “funny" and  
sm ells like "so lvent." You learn that a chem ical p lant was adjacent to his property until 9 years  
ago when the com pany m oved to another location. You are concerned about your patient's  
description o f his drinking water, and you request that the state health departm ent investigate  
the problem . The investigato r contacts the chem ical com pany that owns the abandoned site and  
learns that benzene is stored at the site in tanks that are above and below  ground. Laboratory 
analyses o f the patien t's  well water reveal an average concentration o f 20 ppm  benzene and  
traces o f 1,1,1-trichloroethane and toluene.
What areas w ill you explore in you r questioning to gauge the extent o f the patient's exposure 
to benzene ?
1 1 1 4 3 2 -
Who’s at Risk
=/\t s d r ___________
Two to three million 
U.S. workers are at risk 
of benzene exposure.
Alcohol and other drugs that 
induce the mixed function 
oxidase (MFO) enzymes may 
potentiate the effects of 
benzene.
Workers employed in industries using or producing benzene 
have the greatest likelihood of exposure. The National Institute 
for Occupational Safety and Health (NIOSH) estimates that 
approximately two to three m illion workers in the United States 
may be exposed to benzene during refining operations; gasoline 
storage, shipment, and retail operations; chem ical m anufactur­
ing; plastics and rubber m anufacturing; shoe manufacturing; 
printing; and activities in chemical laboratories. A review of 
benzene exposure in the U.S. petroleum industry from  1978 to 
1983 indicated that 87% of exposures were below an 8-hour time- 
weighted average (TWA) of 1 ppm and 98% were below 10 ppm.
In 1980, an estimated 37 million people in this country were 
exposed to benzene vapors at self-service gasoline stations. 
During gasoline pumping, atmospheric benzene levels up to 6.6 ppm 
have been measured, with a 6-hourTWA of 0.1 ppm. This risk has 
been lowered by installing vapor recapture devices on delivery 
hoses, which, if used properly, s ignificantly reduce exposure. 
Catalytic converters have significantly reduced the benzene in 
automobile emissions.
Benzene is converted to toxic metabolites mostly by mixed- 
function oxidases (MFO) in the liver and bone marrow. MFO- 
inducing drugs (e.g., phénobarbital, alcohol) and certain chem i­
cals (e.g., chlordane, parathion) may increase the rate at which 
toxic metabolites of benzene are formed. Theoretically, persons 
with rapidly synthesizing marrows— the fetus, infants and ch il­
dren, persons w ith hemolytic anemia or w ith agranulocytosis—  
are at increased risk.
JCficUCengi
(2) Does the pa tien t in the case study have any risk factors fo r the adverse effects o f benzene? Is 




Benzene is absorbed rapidly by inhalation and ingestion, and 
slowly through intact skin. A fter a 4-hour exposure to approxi­
mately 50 ppm benzene in air, human volunteers absorbed 
about 50% of the amount inhaled.
Distribution of benzene to tissues is dependent on relative perfu­
sion rates. In humans, approxim ately half of an inhaled dose is 
distributed to the liver and bone marrow. Benzene accumulation 
is slow in fat, but the tota l potentia l uptake is great because of 
benzene’s high lipid solubility.
Absorbed benzene is metabolized primarily in the liver. Benzene 
metabolism initially involves oxidation, with phenol as the major 
metabolite. Further metabolic products formed by the introduction 
of hydroxyl groups on the aromatic ring include hydroquinone, 
catechol, and 1,2,4-trihydroxybenzene. These hydroxylated me­
tabolites can be further oxidized to their corresponding quinones 
or semiquinones. Urinary excretion of small amounts of muconic 
acid, a straight-chain dicarboxylic acid, indicates that the ben­
zene ring also is opened during metabolism.
Bone marrow is the main target organ of benzene toxicity. It 
contains the MFO enzymes necessary to metabolize benzene, 
and although benzene metabolism in bone marrow is not clearly 
understood, one or more benzene m etabolites are suspected as 
responsible fo r the hem atotoxicity. The m etabolites may bind 
covalently to ce llu lar macromolecules (e.g., proteins, DNA, and 
RNA), causing disruption of cell growth and replication. The rate 
of benzene metabolism  in bone marrow is lower than that in the 
liver.
Approxim ately 50% of absorbed benzene is excreted unchanged 
via the lungs over a 36-hour period, depending on exercise level 
and amount of body fat. Respiratory elim ination is triphasic, w ith 
approximate half-lives of 1 hour, 3 hours, and greater than 15 
hours. Urinary excretion of metabolites, prim arily phenol, is 
another im portant pathway for elim ination. Most of the phenol is 
excreted in the form  of sulfate esters and glucuronides. A fter a 
single exposure, urinary excretion of phenol and hydroquinone 
is highest w ith in the firs t 24 hours and is essentia lly complete 
w ith in 48 hours.
□  Benzene is absorbed well 
after inhalation or ingestion; 
In comparison, dermal 
absorption Is slow.
□  Benzene Is metabolized in the 
liver and bone marrow.
□  Benzene excretion occurs 
via the lungs and urine.
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= / \ t s d r __________________
Benzene exposure affects the central nervous system (CNS) and 
hematopoietic system and may affect the immune system. Death 
due to acute benzene exposure has been attributed to asphyxi­
ation, respiratory arrest, CNS depression, or cardiac dysrhythmia. 
Pathologic findings in fatal cases have included respiratory tract 
inflammation, lung hemorrhages, kidney congestion, and cere­
bral edema.
□  Benzene affects primarily 
the CNS and hematopoietic 
system.
Central Nervous System Effects
At very high concentrations, 
benzene rapidly causes CNS 
depression, which can lead to 
death.
Acute benzene exposure results in classic symptoms of CNS 
depression such as dizziness, ataxia, and confusion. General 
agreement that benzene itself is responsible fo r central nervous 
system effects, and benzene metabolite(s) are responsible for 
the observed blood dyscrasias, has evolved from temporal 
studies and the fact that agents known to alter benzene metabo­
lism also alter benzene hematotoxicity.
Hematologic Effects
□  All three blood cell lines 
may be adversely affected 
by benzene.
□  Pluripotentlai stem cells 
and lymphocytic cells are 
the probable targets of 
benzene toxicity.
All three cell lines— erythrocytes, leukocytes, and platelets— may 
be affected by benzene to varying degrees. Benzene’s most 
likely target is the DNA of the p luripotentia l stem and lymphocytic 
cells. Hematologic abnormalities such as anemia, leukopenia, 
throm bocytopenia, or pancytopenia may occur after chronic 
exposure. Potentially fatal infectionscan develop if granulocytopenia 
is present, and hemorrhage can occur as a result of throm bocy­
topenia. Paroxysmal nocturnal hem oglobinuria, a rare paraneo­
plastic disorder, has been associated w ith benzene exposure. 
Cytogenetic abnormalities of bone marrow cells and circulating 
lymphocytes have been observed in workers exposed to ben­
zene, abnorm alities not unlike those observed after exposure to 
ionizing radiation. Myelodysplastic effects also can be seen in 
the bone marrow of persons chronically exposed to benzene.
Anemia
Benzene-induced aplastic 
anemia Is caused by chronic 
exposure at relatively high 
levels.
Fatal aplastic anemia was first reported in benzene-exposed 
workers in the nineteenth century. Aplastic anemia is a condition 
caused by bone marrow failure, resulting in hypoplasia w ith an 
inadequate number of all cell lines. Generally, benzene-induced 
aplastic anemia is caused by chronic exposure at relatively high 
doses. No overt cytopenic effects have been observed in persons 
exposed at the previous workplace permissible exposure limit of
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10 ppm. Severe aplastic anemia typically has a poor prognosis 
and can progress to leukemia, whereas pancytopenia may be 
reversible.
Leukemia
The causal relationship between benzene exposure and leuke­
mia, which has been suspected for over 50 years, has only 
recently been accepted widely. Lack of adequate epidemiologic 
data and difficulty in producing hematologic carcinogenicity in 
animals impeded a consensus. Cohort studies of benzene- 
exposed workers in several industries (sheet rubber manufactur­
ing, shoe manufacturing, rotogravure printing) have demonstrated 
significantly elevated risk of leukemia, predominantly acute my­
e logenous leukem ia, but also e ry th ro leukem ia  and acute 
m yelomonocytic leukemia. For benzene-induced leukemia the 
latency period is typically 5 to 15 years after first exposure. 
Patients with benzene-induced aplastic anemia have been ob­
served to progress to a preleukemic phase and develop acute 
myelogenous leukemia. However, a person exposed to benzene 
may develop leukemia w ithout having aplastic anemia.
Studies addressing the risk of leukemia associated with low-level 
benzene exposures have been inconclusive. Death certificates 
do not reveal increased leukemia mortality among workers poten­
tia lly exposed to low levels of hydrocarbons and other petroleum 
products. However, in one recent case-control study, significantly 
more patients with acute nonlymphocytic leukemia were em­
ployed as truck drivers, filling station attendants, or in jobs 
involving exposure to low levels of petroleum products than 
among the controls.
Other Effects
Several reports relate benzene exposure to a variety of lym­
phatic tum ors including non-Hodgkin 's lymphoma and multiple 
myeloma. A lthough th is is plausible, no scientific proof of a 
causal re lationship exists. The association between exposure to 
benzene and developm ent of nonhematologic tumors remains 
inconclusive.
Inform ation on the reproductive toxicity of benzene in humans is 
meager. Benzene has not been proven teratogenic in humans or 
animals at doses that do not produce maternal toxicity.
□  Benzene-Induced leukemia 
has a usual latency period of 
5 to 15 years and, In many 
cases, is preceded by aplas­
tic anemia.
□  The evidence is insufficient 
to Indicate a causal relation­
ship between benzene and 
nonhematologic tumors.
□  Teratogenic effects due to 
benzene have been observed 
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History and Physical Examination
In addition to a thorough medical history and physical examina­
tion, important factors in evaluating a patient potentially exposed 
to benzene include a detailed family history of blood dyscrasias 
including hematologic neoplasms, genetic hemoglobin abnor­
malities, bleeding abnormalities, and abnormal function of formed 
blood elements; an environmental history focusing on activities 
and possible sources of benzene exposure at home; and an 
occupational history, including past exposures to hematologic 
toxicants such as solvents, insecticides, and arsenic. A history of 
ionizing radiation exposure, medications, and smoking should 
also be explored.
Signs and Symptoms 
Acute Exposure
Acute benzene exposure 
causes CNS depression.
Acute benzene toxicity is characterized by central nervous sys­
tem depression. Symptoms may progress from light-headedness, 
headache, and euphoria, to respiratory depression, apnea, coma, 
and death. Benzene concentrations of about 20,000 ppm are fatal 
to humans within 5 to 10 minutes.
“Benzol jag” is a term workers use to describe symptoms of 
confusion, euphoria, and unsteady gait associated with acute 
benzene exposure. Depending on the magnitude of the dose, 
persons who have ingested benzene may experience these 
effects 30 to 60 minutes after benzene ingestion. In one case 
report, an oral dose of 10 m illiliters (mL) was reported to produce 
staggering gait, vomiting, tachycardia, pneumonitis, somnolence, 
delirium, seizures, coma, and death.
Chronic Exposure
□  Symptoms of chronic benzene 
exposure may be nonspecific, 
such as fatigue and anorexia.
Early symptoms of chronic benzene exposure are often nonspe­
cific but show marked individual variability. By the time a physi­
cian is consulted, the bone marrow may have been affected 
significantly. For example, conditions that first bring the patient to 
medical attention are typically fever due to infection or manifesta­
tions of thrombocytopenia, such as hemorrhagic diathesis with 




The clinical picture of patients chronically exposed to benzene 
was described well in 1938 in a cohort study of about 300 workers 
in the rotogravure printing industry. At that time, ink solvents and 
th inners containing 75% to 80% benzene by volume were used in 
the pressroom. Initial physical exam ination of the workers was 
re latively unrevealing, but of those tested, 22 persons had 
severe hem atologic abnorm alities. Follow-up of the workers a 
year after exposure ceased suggested that the effects of ben­
zene can persist or can evolve over time. Most patients recover 
a fter exposure ceases.
Laboratory Evaluation
Laboratory evaluation of benzene-exposed persons should in­
clude the following:
CBC with d ifferentia l, hematocrit, hemoglobin, erythro­
cyte count, erythrocyte indices (MCV, MCH, MCHC), and 
platelet count.
Plasma folate and vitam in B12 levels may be used to rule out 
megaloblastic anemia if the MCV is elevated.
The above laboratory tests w ill detect hematologic abnormalities 
that have been associated with relatively high levels of exposure 
to benzene. Persons w ith blood dyscrasias that persist after 
removal from  exposure should be evaluated by a hematologist. 
Bone marrow aspiration and biopsy may be useful in narrowing 
the d ifferentia l diagnosis in some cases.
Direct Biologic Indicators
Measurement of benzene in breath and blood can be useful in 
certain occupational settings. Because of benzene’s relatively 
short b iologic half-life, blood levels do not reflect cum ulative 
body burden. A less invasive measurement of exposure in the 
workplace may be the benzene concentration in end-expired air. 
Studies show that 16 hours after an 8-hour exposure to benzene 
levels of 10 ppm and 1 ppm, steady-state exhaled benzene 
concentrations are 50 ppb and 10 ppb, respectively. However, 
these methods are not clin ica lly useful for patients exposed to 
the low levels of benzene typically found in ambient air.
Urinary phenol concentrations generally correlate well with ben­
zene exposure at concentrations above 10 ppm. Exposure to 
10 ppm fo r 8 hours typically produces a postshift urinary phenol 
level of 45 to 50 m illigrams per liter (mg/L). W ith exposure to air 
levels below 10 ppm, high background excretion of phenol from 
dietary and o ther sources can render urinary phenol levels
□  Hematologic abnormalities 
are the primary concern in 
benzene exposure.
□  Measurement of benzene In 
blood and breath Is generally 
not clinically useful in 
nonoccupational settings.
□  Urinary phenol concentra­
tions do not correlate with 
airborne benzene levels 
below 10 ppm.
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unreliable. Unexposed persons rarely have urinary phenol levels 
greater than 20 mg/L.
Indirect Biologic Indicators
An increase in MCV and a decrease in total lymphocytes may be 
early signs of benzene toxicity. A finding of benzene-induced 
hematotoxicity in a patient should trigger consideration that this 
represents a sentinel event, indicating that other persons may 
have been sim ilarly exposed.
If aplastic anemia is suspected, a bone marrow aspiration and 
biopsy should be performed. Aspiration of the marrow space often 
produces no sample (dry tap) in patients with aplastic anemia; 
however, a dry tap is not diagnostic of aplastic anemia; therefore, 
a biopsy specimen should be obtained as well and examined for 
architecture and cellularity. In aplastic anemia, only the empty 
reticular meshwork of the marrow is evident with fat cells replac­
ing all or most of the hematopoietic tissues. Islands of residual 
hematopoiesis may be seen, but the overall cellularity typically is 
less than 25%. Chrom osom al changes consistent w ith myelo­
dysplasia are seen on cytogenetic analysis.
(3) What should be included in the problem  list o f the patien t described in the case study?
(4) Add itiona l Inform ation for the Case Study: A bone m arrow aspiration reveals fibrous and fatty  
structures with very few  spicules including m ononuclear phagocytes, reticulum  cells, and  
plasm a cells. Rare prom yelocytes and m egaloblastic nucleated erythro id cells are present. No 
megakaryocytes are observed.
What d iffe rentia l d iagnosis do the patient's hem atologic results suggest?
(5) What additional laboratory testing would you recommend?
□  MCV and lymphocyte count 
may aid In the diagnosis of 
benzene toxicity.
□  A bone marrow aspiration 






Treatm ent fo r persons acutely exposed to benzene is generally 
supportive and sym ptom atic. Immediate removal of the patient 
from  exposure and adm inistration of oxygen and cardiopulm on­
ary resuscitation measures are the first consideration. In cases 
of ingestion, respiratory distress may indicate pulmonary aspira­
tion of gastric contents.
Contam inated clothing and shoes should be removed from an 
exposed person as soon as possible. If the skin or eyes have 
contacted liquid benzene, im mediately wash the exposed skin 
w ith soap and copious water, and irrigate the eyes w ith running 
w ater fo r 3 to 5 minutes or until irritation ceases.
In cases of ingestion, emesis is recommended in alert adult 
patients if less than 1 hour has passed since ingestion. However, 
if CNS o r respiratory depression are present or likely, emesis is 
contraindicated. Care must be taken to avoid aspiration of 
stomach contents during vom iting because benzene can pro­
duce a severe chem ical pneum onitis. Gastric lavage may be 
preferable to emesis if large amounts of benzene have been 
ingested or if the patient is seen more than 1 hour after ingestion. 
Activated charcoal decreases benzene absorption in experi­
mental animals, and the benefits are likely to be sim ilar in 
humans.
W hen medically indicated, epinephrine should be used cau­
tiously with careful cardiac monitoring. Benzene is one of sev­
eral solvents that may increase the susceptib ility of the m yocar­
d ium  to the dysrhythm ogenic effects of catecholam ines.
Chronic Exposure
In treating persons chronically exposed to benzene, the most 
important actions are to remove the patient from  the source of 
benzene exposure and to prevent fu rther exposure. Benzene- 
induced depression of blood elem ents generally reverses after 
exposure is term inated. Chronically exposed patients whose 
hem atologic results do not return to normal despite removal from 
exposure should be managed in consultation w ith a hem atolo­
gist or oncologist. Chem otherapy and bone marrow transplants 
are therapeutic options fo r leukemia and aplastic anemia, re­
spectively.
□  There Is no antidote for acute 
benzene poisoning.
□  Treatment for benzene 
toxicity is supportive and 
symptomatic.
□  Once chronic exposure to 
benzene ceases, hematologic 





(6) W hat are some key considerations in the treatm ent fo r the pa tien t in the case study?




The current permissible In 1987, the Occupational Safety and Health Administration (OSHA)
exposure limit for benzene instituted a perm issible exposure limit fo r benzene of 1 ppm,
is 1 ppm. measured as an 8-hour time-weighted average (TWA), and a short­
term exposure limit of 5 ppm (Table 1). These legal limits were 
based on studies demonstrating compelling evidence of health 
risk to workers exposed to benzene. The risk from exposure to 
1 ppm for a working lifetime has been estimated to be 5 excess 
leukemia deaths per 1000 employees exposed. (This estimate 
assumes no threshold for benzene’s carcinogenic effects.) OSHA 
has also established an action level of 0.5 ppm to encourage even 
lower exposures in the workplace.
The National Institute fo r Occupational Safety and Health (NIOSH) 
recommends an exposure lim it of 0.1 ppm as a lo -hou r TWA. 
NIOSH also recommends that benzene be handled in the w ork­
place as a human carcinogen.
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Table 1. Standards and regulations for benzene
Agency * Focus Level Comments
ACGIH Air-workplace 10 ppm Advisory; 8-hour TWA^; suspected 
human carcinogen
NIOSH Air-workplace 0.1 ppm Advisory; 10-hour TWA
1.0 ppm 15-min ceiling limit
OSHA Air-workplace 1 ppm Regulation; 8-hour TWA
5 ppm 15-min STEL§
EPA Drinking water 5 ppb Regulation; maximum contaminant 
level
FDA Food N/A Regulation; may be used only as a 
component of packaging adhesives
ACGIH = American Conference of Governmental Industrial Hygienists; EPA = Environmental Protection 
Agency; FDA = Food and Drug Administration; NIOSH = National Institute for Occupational Safety and 
Health; OSHA = Occupational Safety and Health Administration
t  TWA (time-weighted average) = time-weighted average concentration for a normal workday and a 
40-hour workweek to which nearly all workers may be repeatedly exposed.
§
STEL (short-term exposure limit) = usually determined by a 15-minute sampling period.
Environment
Air
Benzene has been designated as a hazardous air pollutant □  EPA restricts benzene
under section 112 of the Clean A ir Act. EPA has not promulgated emissions from specific point
a specific am bient air standard for benzene but has imposed sources.
restrictions designed to lower industrial em issions of benzene by
90% over the next 20 years. In addition, regulations have been
proposed that would control benzene em issions from industrial
solvent use, waste operations, transferoperations, and gasoline
marketing. At gas stations, proposed rules would require new
equipment restricting benzene em issions while dealers' storage
tanks are being filled.
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Water
The National Primary Drinking W ater Regulations promulgated by 
EPA in 1987 set a maximum contaminant level to r benzene of
0.005 ppm (5 ppb). This regulation is based on preventing ben­
zene leukemogenesis. The maximum contam inant level goal 
(MCLG), a nonenforceable health goal that would allow an ad­
equate margin of safety for the prevention of adverse effects, is 
zero benzene concentration in drinking water.
= / \ t s d r _________________________________________________________________
Food
Effective April 1988, the Food and Drug Adm inistration has 
mandated that benzene can only be an indirect food additive in 
adhesives used for food packaging.
ChaCCenge.
(8) The lawyer fo r the fam ily o f the pa tien t in the case study approaches you and asks you  
to establish causality between the patient's condition and the benzene in the drinking  
water. How would you do so?
□  The maximum contaminant 
level of benzene in drinking 
water is 5 ppb.
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Sources of Information
More information on the adverse effects of benzene and the treatm ent and management of benzene- 
exposed persons can be obtained from ATSDR, your state and local health departm ents, and university 
medical centers. Case Studies in Environm enta l M edicine: Benzene Toxicity is one of a series. For other 
publications in this series, please use the order form on the back of page 21. For c lin ical inquiries, contact 
ATSDR, D ivision of Health Education, Office of the Director, at (404) 639-6204.
In addition to other resources, ATSDR has created a National Exposure Registry fo r benzene. This registry 
is one of a series mandated by the Com prehensive Environmental Response, Compensation, and Liability 
Act of 1980 (CERCLA). ATSDR, in cooperation with the states, will establish and m aintain national registries 
of (1) persons exposed to substances and (2) persons with serious illness or diseases possibly due to
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exposure. The registries w ill co llect information on the effects of low-level exposures of long duration 
(i.e., the exposures typically found in populations surrounding hazardous waste sites) and the health 
outcomes for populations receiving a one-time, high-level environm ental exposure (such as those 
experienced at chem ical spill sites). The registries w ill facilita te the identification and subsequent 
tracking of persons exposed to a defined substance at selected sites and w ill coordinate the clinical 
and research activ ities involving the registrants. For further information on the benzene registry, 
p lease contact ATSDR Division of Health Studies, O ffice of the Director, at (404) 639-6200.
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Answers to Pretest and Challenge Questions
Pretest questions are found on page 1; answers are in (3) through (7) below. Challenge questions begin 
on page 3.
(1) Some important areas to explore include amounts and duration of exposure from  the follow ing sources:
-  w ater supply (ingestion)
-  w ater supply (inhalation or dermal absorption during bathing and laundering)
-  am bient air (fugitive em issions from the chemical plant during its operation and since it was
abandoned 9 years ago)
-  occupation (activities, conditions, and time spent as a diesel mechanic)
-  workplace conditions (cleaning of machinery parts, solvents used, protective equipment worn, and
the adequacy of ventilation)
-  home environment (use of consum er products that might contain benzene, exposure to personal or
passive cigarette smoke)
(For more information, see Case Studies in Environm ental M edicine: Taking an Exposure History, 
ATSDR, October 1992.)
(2) Theoretically, a person could be at increased risk of benzene's adverse effects if he or she encountered 
agents or conditions that increased the rate of form ation of toxic benzene metabolites through induction 
of the MFO system. Potential agents include MFO-inducing drugs (e.g., phenobarbital, alcohol); 
conditions include those causing rapid synthesis of bone marrow. The patient only occasionally drinks 
beer and did not take medications before his illness, and so he avoids the risk factors of alcohol and 
m edications. However, if the patient is suffering from a hematologic abnormality, as his symptoms and 
laboratory evaluation suggest, he w ill have increased risk if benzene exposure continues.
O ther persons in the case who may be at increased risk of benzene exposure are those who have had 
contact w ith the water supply fo r a prolonged period of time, although no data exist to quantita te the risk. 
Included are persons who have lived in the patient’s household and members of the community who 
share the water supply. Community and household members who are at increased risk of benzene's 
adverse effects theoretically include those w ith rapidly synthesizing bone marrows and persons with 
increased MFO-mediated metabolism (e.g., heavy drinkers).
(3) The patien t’s problem  list includes a clotting disorder, fatigue, ecchymoses and petechiae, and 
anorexia w ith concom itant weight loss.
(4) The hematology study reveals significant thrombocytopenia, leukopenia, and erythropenia. Pancytopenia 
is caused by the accelerated destruction or decreased production of all cell lines including red blood 
cells, white blood cells, and platelets. Bone marrow disorders are likely to be the cause, and could result 
from  the follow ing: drug and chem ical toxic ity (such as benzene toxicity), radiation, infection, nutrient 
defic iencies (e.g., vitam in B12 and folate), hypersplenism, and marrow replacement syndromes.
(5) Additional testing for the patient might include coagulation factors, evaluation for infectious agents, and 
assessm ent of nutrient status. Evaluation of the bone marrow should include a search fo r malignant 
cells. Cytogenetic abnorm alities, if observed, may be helpful in the evaluation but are not definitive.
(6) The patient must be removed from exposure to benzene and other hematologic toxicants. His home 
w ater fo r drinking and personal purposes should be obtained from  a source w ith no detectable level of
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benzene. W ork exposure to toxic chem icals must be carefully evaluated. Adequate nutrients (vitam ins 
and protein source) in his diet should be assured. Care to prevent injury and bleeding must be 
exercised until proper blood coagulation (platelets and other factors) has returned, and the patient 
should be carefu lly monitored for infection in the event of severe granulocytopenia. Prophylactic 
antib iotics and blood transfusions should be avoided unless a significant deterioration of his condition 
becomes evident.
(7) The prognosis is generally good for the resolution of the macrocytosis. A lthough this patient has a 
significant aplastic anemia, it is possible fo r his bone marrow to recover slowly if the damage has not 
reached an irreversible stage. Supportive treatm ent w ill be needed for many months. Because of the 
continued risk of leukemia, the patient should receive medical surveillance consisting of regularly 
scheduled exam inations and appropriate testing of hematologic function. The peripheral smear and 
blood count w ill perm it monitoring of early changes of the patient's condition. Bone marrow biopsy 
should be repeated in a few weeks to confirm initial findings and observe an expected bone marrow 
recovery.
(8) One step in your quest to establish a causal re lationship between benzene-contam inated home water 
and the patient's condition would be to further investigate competing causes of low blood counts for 
this patient (e.g., drugs, radiation exposure, fam ily history), keeping in mind that most cases of aplastic 
anemia are idiopathic. You would also need to explore the patient's potentia l exposure to chem icals 
o the rthan  benzene that might cause hematologic disorders. Finally, assuming the patient's condition 
is due to benzene exposure, you would need to weigh the significance of benzene sources other than 
the drinking water. For example, the patient is a diesel mechanic and most likely has inhalation and 
dermal exposure to gasoline (which contains benzene) at work. You would need to determ ine the 
amounts of benzene each source might have contributed to the patient's exposure. (See answer 
num ber 1 above.)
For the patient in the case study, as fo r most exposure cases, it w ill not be an easy matter to establish 
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Circle all correct responses and record your answers on page 21.
1. W hich of the fo llow ing statem ents about benzene exposure are true?
a. The odor of benzene serves as an adequate warning property in the workplace.
b. Benzene vapor may emanate from products in the home.
c. In the United States, benzene is no longer found in com m ercial gasoline.
d. Possible routes of benzene exposure include dermal absorption.
e. Benzene in the w ater supply could expose persons by ingestion, inhalation, and dermal 
absorption.
2. Smokers may be at increased risk of benzene exposure because
a. carbon monoxide potentiates the effects of benzene
b. c igarette smoke contains toluene, which is metabolized to benzene
c. sm okers drink less alcohol as they smoke
d. inhaled cigarette smoke contains benzene
e. sm okers are more sensitive to benzene's CNS effects
3. An appropriate bio logic measure of high-dose benzene exposure may be
a. blood benzene concentration
b. benzene levels in end-expired air
c. thyro id function tests
d. tissue benzene concentration
e. urinary phenol level
4. Hem atologic abnorm alities associated with benzene toxicity may include
a. leukopenia




5. W hich of the fo llow ing statements about benzene metabolism are true?
a. The m etabolic fate of absorbed benzene depends on the route of exposure.
b. Benzene’s hem atotoxicity is probably due to the effects of active metabolites.
c. Only the liver can m etabolize benzene.
d. Benzene’s m etabolites may bind covalently to cellu lar macromolecules.
e. Ethanol prevents the m etabolism of benzene.
6. Pancytopenia may be caused by
a. certain m edications such as aspirin
b. heavy metals such as arsenic
c. nonionizing radiation
d. vira l infections such as hepatitis
e. certain insecticides
7. Treatm ent of chronic benzene toxicity would include
a. adm inistration of pressor agents to sustain blood pressure
b. imm ediate removal of the patient from the source of exposure
c. adm inistration of large doses of catecholam ines
d. adm inistration of hyperbaric oxygen and intravenous flu ids
e. sym ptom atic and supportive measures
8. Benzene exposures have been reported to occur during
a. shoe m anufacturing
b. rocket fuel form ulating
c. b lueprint drawing




CASE STUDIES IN ENVIRONMENTAL MEDICINE: BENZENE TOXICITY
If you wish CME credits or CEU, please indicate your answers to the Posttest questions on page 20 by circling 
the letters below for the correct answers. Complete the evaluation questionnaire and fill in the information 
requested on the reverse side. Tear off this last page, fold, staple, and mail to Continuing Education Coordinator, 
Agency for Toxic Substances and Disease Registry, Division of Health Education, E33, 1600 Clifton Road, NE, 
Atlanta, GA 30333.
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2. a b c d e
3. a b c d e
4. a b c d e
5. a b c d e
6. a b c d e
7. a b c d e
8. a b c d e
Evaluation Questionnaire
Please complete the following evaluation by putting a check in the appropriate box.
YES
1. As a result of completing this monograph, I will be able to:
Explain why benzene may be an acute and chronic health hazard. □
Describe the factors that may contribute to benzene poisoning. □
Identify potential environmental and occupational sources of benzene 
exposure. □
Identify evaluation and treatment protocols for persons exposed to benzene. □
List sources of information on benzene. □
2. I am more likely to ask patients questions regarding possible environmental 
exposures as a result of reading this issue. □
3. I would recommend this issue to my colleagues. □
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□ Benzene □ Jet Fuels 4 and 7 □ Tetrachloroethylene
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□ Cholinesterase Inhibitors □ Nitrates/Nitrites □ Exposure History
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The state of knowledge regarding the treatment of patients potentially 
exposed to hazardous substances in the environment is constantly evolving 
and is often uncertain. In this monograph, the Agency for Toxic Substances 
and Disease Registry (ATSDR) has made diligent effort to ensure the 
accuracy and currency of the information presented but makes no claim that 
the document comprehensively addresses all possible situations related to 
this topic. This monograph is intended as an additional resource for physi­
cians and other health professionals in assessing the condition and managing 
the treatment of patients potentially exposed to hazardous substances. It is 
not, however, a substitute for the professional judgment of a health care 
provider and must be interpreted in light of specific information regarding the 
patient available to such a professional and in conjunction with other sources 
of authority.
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